Soluble endoglin in the pathogenesis of preeclampsia: investigation of mechanisms and the development of therapeutics
Grant number: 1048707 | Funding period: 2013 - 2015
Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver babies irrespective of gestation. We have identified MMP-14 as the molecular scissors that release soluble endoglin from placenta, a toxin centrally responsible for severe preeclampsia. In this project we aim to further investigate the mechanisms governing soluble endoglin release and to begin developing a potential therapeutic for use in the clinic.
Related publications (9)
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
Fiona C Brownfoot, Stephen Tong, Natalie J Hannan, Roxanne Hastie, Ping Cannon, Tu'uhevaha J Kaitu'u-Lino
Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion
Stephen Tong, Tu'uhevaha J Kaitu'u-Lino, Kenji Onda, Sally Beard, Roxanne Hastie, Natalie K Binder, Cathy Cluver, Laura Tuohey, Clare Whitehead, Fiona Brownfoot, Manarangi De Silva, Natalie J Hannan